About the Journal

About the Journal

About the ASIDE Oncology Journal

Publisher and Academic Oversight

ASIDE Oncology Journal is published and owned by PubPorta Publishing LLC, 16192 Coastal Highway, Lewes, Delaware 19958, USA.

Academic oversight and scholarly guidance are provided by the American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE).

Publisher Transition Notice

Effective February 2026, the ownership and publishing responsibilities of ASIDE Oncology Journal were transferred from the American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE) to PubPorta Publishing LLC.
This transition does not affect the journal’s aims, scope, editorial independence, peer-review process, or open-access policies. All previously published content remains accessible under the same licensing terms. ASIDE continues to provide academic and scholarly guidance.

Vision and Mission

The ASIDE Oncology Journal is a peer-reviewed, open-access journal committed to advancing diversity, equity, inclusion, and accessibility in oncology through scholarly publication. As an integral part of ASIDE Healthcare, the journal strives to reflect these values in all its activities and publications.

Our mission is to advance the field of oncology by promoting innovative research, evidence-based practices, and transformative ideas that prioritize health equity. We aim to serve as a platform for voices historically underrepresented in cancer research, offering insights that challenge traditional narratives and foster a more inclusive oncology landscape.

Scope

ASIDE Oncology publishes original research articles, reviews, clinical case studies, and commentary across all subspecialties of oncology. This includes, but is not limited to, medical oncology, surgical oncology, radiation oncology, hematologic malignancies, cancer epidemiology, palliative care, supportive oncology, and cancer survivorship. We particularly value contributions that address the impact of social determinants of health, innovative patient care strategies for underserved cancer populations, health disparities, and interdisciplinary approaches to complex oncologic challenges.

Readership

Our readership includes oncologists, cancer researchers, multidisciplinary healthcare professionals, policy makers, advocates, and educators who are dedicated to transforming cancer care and outcomes for all. With a global outreach, ASIDE Oncology invites submissions from around the world to foster diverse, international dialogue in oncology.

Publication Frequency

ASIDE Oncology Journal is published quarterly, with four issues per year. Articles are published online as soon as they complete peer review and production, then assembled into the next available issue.

Language

The journal publishes in English.

Open Access & Licensing Policy

ASIDE Oncology provides immediate open access to all content. The full text of every article is freely available to read, download, copy, distribute, print, search, or link to without delay, with no embargo and no registration requirement.

Unless otherwise indicated, all articles are published under the Creative Commons Attribution 4.0 International (CC BY 4.0) license (legal code). This license permits use, sharing, adaptation, distribution, and reproduction in any medium or format, including commercial use, provided appropriate credit is given to the original authors and the source, a link to the license is provided, and changes are indicated.

Authors retain copyright to their work and grant the publisher a non-exclusive right of first publication under the above license. The copyright holder and license are clearly displayed on each article’s HTML page and PDF.

 Content (e.g., images, figures, data) not covered by CC BY 4.0 is identified by a credit line noting the different terms. Permission may be required for uses beyond those allowed by the stated license.

The journal charges no submission or publication fees (no APCs).

Direct Marketing Policy

ASIDE Oncology may occasionally send targeted calls for papers or informational messages to researchers whose expertise aligns with the journal’s aims and scope. Any outreach conducted on behalf of the journal is appropriate, well-targeted, and unobtrusive. All information about the journal and publisher is truthful and not misleading.

We do not guarantee acceptance, indexing, or publication outcomes in any communication, and we do not request or require payment as a condition of submission. Messages clearly identify the journal and publisher, the article types sought, relevant deadlines, and link to our policies. Recipients can opt out at any time, and we promptly honor unsubscribe requests. We do not buy third-party email lists; contact details are gathered from publicly available academic sources or prior voluntary interactions. Outreach practices comply with applicable regulations (e.g., CAN-SPAM/GDPR).

Editorial Process

Our rigorous peer-review process ensures the publication of high-quality research. The journal upholds the highest standards of peer review, managed by an international editorial board dedicated not only to advancing oncologic science but also to upholding fairness, diversity, and inclusiveness in academic publishing.

Peer Review Policy for ASIDE Oncology: Double-Blind Process

Introduction to Peer Review

1.1 What is Peer Review?
Peer review is a critical process used to ensure the quality and integrity of manuscripts prior to publication. Independent experts assess submissions for originality, validity, and significance to assist editorial decisions about publication suitability.

1.2 Purpose of Peer Review in ASIDE Oncology
Peer review at ASIDE Oncology validates the scientific accuracy and relevance of submitted manuscripts, ensuring that published research is trustworthy and significantly advances the field of oncology.

Types of Peer Review

2.1 Double-Blind Peer Review
ASIDE Oncology uses a double-blind peer review process: both reviewers and authors remain anonymous to each other. This minimizes bias and ensures a fair, impartial evaluation based solely on academic and scientific merit.

3. Double-Blind Peer Review Process

3.1 Manuscript Submission

    • Authors must submit manuscripts through the journal’s online submission system.
    • Manuscript files, supplementary files, figures, and document properties should not contain identifying information such as author names, affiliations, acknowledgments, or self-identifying statements.
    • The editorial office conducts an initial screening to assess scope, compliance with author guidelines, ethical and reporting requirements, and basic scientific and editorial quality.
    • Manuscripts that do not meet these requirements may be returned for technical correction or declined without external review.

3.2 Reviewer Selection

    • Editors select reviewers based on subject expertise, academic qualifications, prior review quality, and the absence of relevant conflicts of interest.
    • Reviewers are chosen for their ability to provide fair, independent, and constructive evaluations.
    • In most cases, manuscripts are sent to at least two qualified reviewers, although this may vary depending on the article type and topic.

3.3 Conducting the Review

    • Reviewers assess originality, relevance, methodological quality, scientific rigor, statistical analysis, interpretation of results, clarity of presentation, ethical conduct, and overall contribution to the literature.
    • All manuscripts must be treated as confidential documents.
    • Reviewers must not share, discuss, or use unpublished material for personal or professional advantage.
    • Any actual or potential conflict of interest must be disclosed before accepting the review invitation.

3.4 Reviewer Recommendations

    • Reviewers may recommend acceptance, minor revision, major revision, or rejection.
    • Reviewers are expected to provide clear, respectful, and constructive comments to support editorial decisions and help authors improve their work where appropriate.

3.5 Editorial Decision-Making

    • The final decision rests with the editor and is based on reviewer comments, the scientific quality of the manuscript, its fit with the journal’s aims and scope, and applicable ethical and editorial standards.
    • When reviewer opinions differ substantially, the editor may seek an additional independent review.

3.6 Revision and Re-review

    • When revisions are requested, authors should submit a revised manuscript together with a clear point-by-point response to reviewer and editor comments.
    • Revised manuscripts may be returned to the original reviewers or assessed by the editorial team, depending on the nature and extent of the revisions.
    • Additional rounds of revision may be required to ensure that scientific, ethical, and reporting concerns are fully addressed.

3.7 Acceptance and Publication

    • Accepted manuscripts proceed to copyediting, formatting, proofreading, metadata preparation, and final author approval before publication.

4. Why Double-Blind Peer Review?

Double-blind peer review helps support fairness, reduce potential bias, and keep the focus on the scientific and scholarly content of each submission.

5. Ensuring Integrity and Fairness

All participants in the peer review process, including authors, reviewers, and editors, are expected to act with honesty, confidentiality, professionalism, and respect. Any attempt to compromise reviewer anonymity, identify participants inappropriately, manipulate the review process, or interfere with the integrity of peer review will be treated seriously and may result in editorial action under the journal’s ethics policies.

6. Conclusion

The peer review process at ASIDE Oncology is designed to uphold high standards of scientific quality, editorial fairness, and publication ethics, and to publish trustworthy and clinically meaningful research that advances Oncology and related fields.

Policies on Editorial Involvement and Endogeny

Policy on Editorial Involvement in Manuscripts

If the Editor-in-Chief, an Associate Editor, or any editorial board member is a co-author on a submission, they must recuse themselves from the review process. A qualified editor without a conflict will manage the review to ensure impartiality.

Editorial members who are co-authors have no access to the review process or influence over decisions regarding their manuscript, ensuring integrity and fairness.

 

Ethical Standards for ASIDE Oncology

Introduction

ASIDE Oncology adheres to the code of ethics outlined by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), the Open Access Scholarly Publishers Association (OASPA), and the Think. Check. Submit. initiative. These guidelines uphold the highest standards of integrity, transparency, and fairness in all publishing practices.

1. Editorial Standards

  • Integrity: Committed to ethical guidelines by COPE and ICMJE.

  • Fair Play: Manuscripts are evaluated solely on content, regardless of race, gender, sexual orientation, religion, ethnicity, citizenship, or political views.

  • Confidentiality: Editorial staff maintain strict confidentiality throughout the review process.

2. Duties of Reviewers

  • Contribution to Decisions: Peer review supports editorial decisions and helps authors improve their work.

  • Promptness: Reviewers should promptly accept or decline invitations, and excuse themselves if unqualified or unavailable.

  • Confidentiality: All submissions are confidential.

  • Objectivity: Reviews are conducted objectively, avoiding personal criticism and providing clear, supported arguments.

  • Conflict of Interest: Reviewers should decline reviews where a conflict exists.

3. Duties of Authors

  • Reporting Standards: Original research must be reported accurately and objectively.

  • Data Access: Authors may be required to provide underlying data.

  • Originality and Attribution: All sources must be appropriately cited.

  • Redundant Publication: Manuscripts should not duplicate previously published work.

  • Authorship: Authorship is limited to those who made significant contributions.

  • Disclosure: All conflicts of interest must be disclosed.

4. Publishing Ethics Issues

  • Monitoring Ethics: The editorial board monitors compliance with COPE guidelines and addresses misconduct.

  • Retraction Policy: In cases of confirmed misconduct, ASIDE Oncology will retract affected publications to protect the scientific record.

Our commitment to ethical practices ensures every article meets the highest standards in biomedical publishing. For questions, contact the editorial office at [email protected].

 

Preservation & Archiving Policy

ASIDE Oncology is committed to the long-term preservation and accessibility of its content through the following:

  • PKP Preservation Network (PKP PN): Application submitted; upon activation, all published content will be preserved automatically through the PKP PN service for OJS journals.

  • Internet Archive: All issues and article PDFs are deposited in the Internet Archive (archive.org) for long-term preservation and public access. Core journal pages are also captured periodically via the Wayback Machine.

  • Institutional & Library Repositories (Self-archiving): Authors are encouraged to deposit all versions—preprint, accepted manuscript, and version of record—without embargo, in institutional or subject repositories of their choice.

  • OAI-PMH: Metadata and content are available for harvesting via our OAI-PMH endpoint: https://asidejournals.com/index.php/oncology/oai

If the journal were to cease publication, archived content will remain permanently accessible via the Internet Archive and any active preservation services (e.g., PKP PN).

Repository & Self-Archiving Policy

ASIDE Oncology permits and encourages authors to deposit all versions of their articles in institutional, subject, funder, or personal repositories, and on academic profiles, without embargo:

  • Submitted version (preprint): may be shared at any time.
  • Accepted version (Author Accepted Manuscript, AAM): may be shared immediately upon acceptance.
  • Published version (Version of Record, VoR): may be shared immediately after publication.

Include a full citation and a link to the Version of Record (article page or DOI) wherever a version is deposited. Articles are published under CC BY 4.0. Journal metadata is harvestable via OAI-PMH: https://asidejournals.com/index.php/oncology/oai.

If the journal were to cease publication, archived content will remain permanently accessible via the Internet Archive and any active preservation services (e.g., PKP PN).

Repository & Self-Archiving Policy

ASIDE Oncology permits and encourages authors to deposit all versions of their articles in institutional, subject, funder, or personal repositories, and on academic profiles, without embargo:

  • Submitted version (preprint): may be shared at any time.
  • Accepted version (Author Accepted Manuscript, AAM): may be shared immediately upon acceptance.
  • Published version (Version of Record, VoR): may be shared immediately after publication.

Include a full citation and a link to the Version of Record (article page or DOI) wherever a version is deposited. Articles are published under CC BY 4.0. Journal metadata is harvestable via OAI-PMH: https://asidejournals.com/index.php/Oncology/oai.

Data Sharing & Reproducibility

ASIDE Oncology supports open, reproducible research. All research articles must include a Data Availability Statement describing where the data, code, and materials that support the findings can be accessed, with persistent identifiers (e.g., DOIs) wherever possible. For clinical trials, authors must provide an ICMJE-compliant data sharing statement.

Underlying data (raw and processed), analysis scripts/code, protocols, and other materials necessary to reproduce the results should be shared unless restricted for ethical, legal, or proprietary reasons. Where restrictions apply, authors must explain them and provide conditions for controlled access.

Deposit datasets in a trusted repository—preferably a discipline-specific repository (e.g., genomic sequences in GenBank; functional genomics data in GEO). When no domain repository fits, use a generalist repository that issues DOIs (e.g., Zenodo, Dryad, OSF). Authors can locate suitable repositories via the re3data registry. Software/code should be in a public version-controlled repository (e.g., GitHub) and archived with a DOI (e.g., via GitHub→Zenodo integration) for citation.

Use open, non-proprietary formats where feasible (e.g., CSV/TSV, JSON, TXT, PNG/TIFF). Provide sufficient documentation/metadata to make data FAIR—Findable, Accessible, Interoperable, and Reusable (e.g., README files, variable dictionaries, licenses).

Human-participant data must be de-identified and shared in line with informed consent, IRB/ethics approvals, and applicable regulations. If data cannot be made public, deposit metadata and specify a controlled access mechanism or qualified point of contact in the Data Availability Statement.

Data and code should be deposited upon acceptance and publicly available upon publication. Include dataset and software citations (with DOIs) in the reference list and provide repository links in the Data Availability Statement.

Publication Ethics

ASIDE Oncology Journal is committed to maintaining high standards of publication ethics and editorial integrity. The journal expects authors, reviewers, editors, and the publisher to act in accordance with accepted principles of responsible scholarly publishing.

The journal’s ethics framework is informed by recognized best-practice guidance, including recommendations from the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), the Open Access Scholarly Publishing Association (OASPA), and the Principles of Transparency and Best Practice in Scholarly Publishing.

Contact

For questions about the journal, editorial policies, or publication ethics, please contact:

ASIDE Oncology Journal
Email: [email protected]

Publisher:
PubPorta Publishing LLC
16192 Coastal Highway
Lewes, Delaware 19958
USA